Cytek Biosciences Inc (CTKB) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Cytek Biosciences Inc stock $2.09, price $5.83, that is 64.2% below the price, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $2.42 – $27.93 · fair‑value band $1.38 – $2.62 · the $5.83 price screens above the $2.09 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Cytek Biosciences in your weekly email
Every Wednesday you see whether Cytek Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications.
Show moreShow less
The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments.
In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the Cytek aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for Cytek aurora, northern lights, and Cytek aurora evo systems; and customer support tools.
Further, it provides conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brand names. The company serves pharmaceutical and biopharma companies, academic research centers, and contract research organizations.
It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries.
The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Stock analysis
Cytek Biosciences Inc (CTKB) currently trades at $5.83, while our model-based Fair Value estimate is $2.09, 64% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $1.38 (bear) to $2.62 (bull), the price of $5.83 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Cytek Biosciences Inc reported revenue of $201M in FY2025 versus $128M in FY2021, a compound +12.0%/yr. Reported net income was −$66.5M in FY2025.
Key figures
Market cap $755M Small · P/S ratio 3.70 · EPS (TTM) $−0.6200 · Net margin −39.0% · Return on equity −23.0% · Return on assets (EBIT) −3.4% (5-year average) · Operating margin −29.5% · Revenue (TTM) $207M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 7% below its 52-week high and 74% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −64%, CTKB screens richer than that median.
Fair Value models
Bear$1.38Fair Value $2.09Bull$2.62
Price $5.83 · Downside -64.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus 18 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+0.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.8%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.1%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
14.7% (2020) → −20.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−64.2% · Bottom 25%
Profitability
Return on assets−14.4% · Bottom 25%
Net margin (12 months)−39.0% · Bottom 25%
Operating margin (12 months)−29.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)5.6% · Below median
Balance sheet
Debt / equity0.00× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B2.21× · Pricier than median
P/S (12 months)3.65× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)28· sector 35
PAST (return on equity)0· sector 17
HEALTH (low debt)100· sector 98
DIVIDEND (yield)0· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Cytek Biosciences Inc (CTKB) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $2.09 versus a price of $5.83, about 64% lower (overvalued).
What is the fair value of CTKB?
Our model-based fair value for Cytek Biosciences Inc is $2.09 (as of Nov 8, 2026), built from audited fundamentals. The current price: $5.83.
What is the quality score of CTKB?
Cytek Biosciences Inc has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cytek Biosciences Inc (CTKB)?
Our model-based price target is the fair value of $2.09 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $1.38, optimistic scenario $2.62. It is a calculation from audited fundamentals, not an analyst target.
What is the Cytek Biosciences Inc stock forecast for 2026?
Our models put fair value at $2.09, about 64% lower versus a price of $5.83 (overvalued). Cautious scenario $1.38, optimistic scenario $2.62. The calculation is refreshed regularly with new filings.
What is the revenue of Cytek Biosciences Inc (CTKB)?
Cytek Biosciences Inc reported trailing-twelve-month revenue of about $207M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Cytek Biosciences Inc (CTKB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cytek Biosciences Inc it is $2.09 per share (as of Nov 8, 2026), against a price of $5.83. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Cytek Biosciences Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, CTKB trades above its calculated fair value: price $5.83, fair value $2.09, a gap of about −64% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CTKB?
No. The price is what the market pays today ($5.83); the fair value is what the company's own numbers justify ($2.09). For Cytek Biosciences Inc the two are $3.74 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cytek Biosciences Inc worth?
The market values Cytek Biosciences Inc at about $755M (market capitalisation, as of Nov 8, 2026). Per share that is $5.83; our models calculate a fair value of $2.09 per share.
What do the bullish and bearish scenarios say about CTKB?
Our models span a range for Cytek Biosciences Inc: cautious scenario $1.38, base $2.09, optimistic $2.62 per share (as of Nov 8, 2026, price $5.83). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cytek Biosciences Inc (CTKB)?
Balance-sheet figures for Cytek Biosciences Inc (as of Nov 8, 2026): return on equity −23.0%, debt of 0.00 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is CTKB from its 52-week high?
Cytek Biosciences Inc trades at $5.83, about 7% below its 52-week high of $6.30 and 74% above the low of $3.36 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $2.09 is for.
Which stocks are comparable to Cytek Biosciences Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cytek Biosciences Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $5.83, calculated fair value $2.09 (−64%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CTKB calculated?
We run Cytek Biosciences Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $2.09 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Cytek Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cytek Biosciences Inc (CTKB)?
The closing price on Nov 6, 2026 was $5.83. Our model-based fair value is $2.09, about 64% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cytek Biosciences Inc right now?
The price sits above even our optimistic bull case ($2.62). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.38 to $2.62) leaves room in how you read the outcome.
Key figures of Cytek Biosciences Inc
How large is the market capitalisation of Cytek Biosciences Inc (CTKB)?
The market capitalisation of Cytek Biosciences Inc is $755M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cytek Biosciences Inc (CTKB)?
The price-to-sales ratio of Cytek Biosciences Inc is 3.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cytek Biosciences Inc (CTKB)?
Earnings per share at Cytek Biosciences Inc are $−0.6200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cytek Biosciences Inc (CTKB)?
The net margin of Cytek Biosciences Inc is −39.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cytek Biosciences Inc (CTKB)?
The return on equity (ROE) of Cytek Biosciences Inc is −23.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cytek Biosciences Inc (CTKB)?
On an EBIT basis the return on assets of Cytek Biosciences Inc is −3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cytek Biosciences Inc (CTKB)?
The operating margin of Cytek Biosciences Inc is −29.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cytek Biosciences Inc (CTKB)?
Revenue at Cytek Biosciences Inc is growing +5.6% versus a year earlier (3y avg +7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cytek Biosciences Inc (CTKB)?
Earnings per share at Cytek Biosciences Inc are growing +73.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Cytek Biosciences Inc (CTKB) generate?
The free cash flow of Cytek Biosciences Inc is −$8.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cytek Biosciences Inc (CTKB) hold?
Cytek Biosciences Inc holds more cash than debt, $67.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Cytek Biosciences Inc in the live analysis
One click puts Cytek Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
